Literature DB >> 3280506

Gd-25 DTPA-MAb, a potential NMR contrast agent for MRI in the xenografted nude mouse: preliminary studies.

C Curtet1, C Bourgoin, J Bohy, J C Saccavini, P Thédrez, S Akoka, C Tellier, J F Chatal.   

Abstract

Monoclonal antibodies (MAbs) 19-9 and 73-3 specific for human colon adenocarcinoma were labelled with a high number of gadolinium atoms. Twenty five DTPA were chelated per MAb, with only slight loss of immunoreactivity. The NMR contrast agent Gd-25 DTPA-MAb 19-9 or 73-3 ([Gd] 17 mumole/kg, [MAb] 60 microM) was injected into nude mice bearing human colon adenocarcinoma (SW948). Tumours were removed 24 hr after injection and T1 was measured in vitro. T1 relaxation time varied according to MAb specificity against tumour targets; T1 decreased 20% for MAb 19-9 and MAb 73-3 with SW948 tumour. Imaging was performed with this model. Very good contrast was obtained 24 hr after Gd-25 DTPA-MAb injection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280506     DOI: 10.1002/ijc.2910410728

Source DB:  PubMed          Journal:  Int J Cancer Suppl        ISSN: 0898-6924


  6 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 2.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography.

Authors:  Kido Nwe; Diane E Milenic; Geoffrey L Ray; Young-Seung Kim; Martin W Brechbiel
Journal:  Mol Pharm       Date:  2011-09-21       Impact factor: 4.939

Review 4.  Antibody-based imaging strategies for cancer.

Authors:  Jason M Warram; Esther de Boer; Anna G Sorace; Thomas K Chung; Hyunki Kim; Rick G Pleijhuis; Gooitzen M van Dam; Eben L Rosenthal
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?

Authors:  Joshua Bryson; Jeffrey W Reineke; Theresa M Reineke
Journal:  Macromolecules       Date:  2012-11-13       Impact factor: 5.985

6.  Novel MR imaging contrast agents for cancer detection.

Authors:  Daryoush Shahbazi-Gahrouei
Journal:  J Res Med Sci       Date:  2009-05       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.